Human HSP70 and modified HPV16 E7 fusion DNA vaccine induces enhanced specific CD8+ T cell responses and anti-tumor effects

Oncology Reports

Volumn 22, Issue 4, 2009, Pages 953-961

  Zong, Jinbao ^a   Peng, Qinglin ^a   Wang, Qingyong ^a   Zhang, Ting ^a   Fan, Dongsheng ^a   Xu, Xuemei ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Cervical cancer; DNA vaccine; E7 gene; Heat shock protein 70; Human papilloma virus 16

Indexed keywords

DNA VACCINE; HEAT SHOCK PROTEIN 70; PROTEIN E7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENTIATION; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; LYMPHOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

ANIMALS; BLOTTING, WESTERN; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MICE; MYCOBACTERIUM TUBERCULOSIS; ONCOGENE PROTEINS, VIRAL; RECOMBINANT FUSION PROTEINS; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA;

EID: 70350359428     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000522     Document Type: Article

References (45)

1. Clifford GM, Smith JS, Plummer M, Munoz N and Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88: 63-73, 2003.
2. Muñoz N, Bosch FX, Castellsagué X, et al: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111: 278-285, 2004.
3. Wu Y, Chen Y, Li L, Yu G, Zhang Y and He Y: Associations of high-risk HPV types and viral load with cervical cancer in China. J Clin Virol 35: 264-269, 2006.
4. Siddiqui MA and Perry CM: Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil): profile report. BioDrugs 20: 313-316, 2006.
5. Crosbie EJ and Kitchener HC: Cervarix - a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer. Expert Opin Biol Ther 7: 391-396, 2007.
6. Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
7. Zehbe I, Wilander E, Delius H and Tommasino M: Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res 58: 829-833, 1998.
8. Gurunathan S, Klinman DM and Seder RA: DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18: 927-974, 2000.
9. Donnelly JJ, Ulmer JB, Shiver JW and Liu MA: DNA vaccines. Annu Rev Immunol 15: 617-648, 1997.
10. Li Z, Menoret A and Srivastava P: Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr Opin Immunol 14: 45-51, 2002.
11. Srivastava P: Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20: 395-425, 2002.
12. Asea A, Kraeft SK, Kurt-Jones EA, et al: HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 6: 435-442, 2000.
13. Singh-Jasuja H, Scherer HU, Hilf N, Arnold-Schild D, Rammensee HG, Toes RE and Schild H: The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur J Immunol 30: 2211-2215, 2000.
14. Kuppner MC, Gastpar R, Gelwer S, Nössner E, Ochmann O, Scharner A and Issels RD: The role of heat shock protein (hsp70) in dendritic cell maturation: hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors. Eur J Immunol 31: 1602-1609, 2001.
15. Massa C, Guiducci C, Arioli I, Parenza M, Colombo MP and Melani C: Enhanced efficacy of tumor cell vaccines transfected with secretable hsp70. Cancer Res 64: 1502-1508, 2004.
16. Hauser H, Shen L, Gu QL, Krueger S and Chen SY: Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Gene Ther 11: 924-932, 2004.
17. Raska M and Weigl E: Heat shock proteins in autoimmune diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149: 243-249, 2005.
18. Steinhoff U, Brinkmann V, Klemm U, et al: Autoimmune intestinal pathology induced by hsp60-specific CD8 T cells. Immunity 11: 349-358,1999.
19. Zugel U and Kaufmann SHE: Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin Microbiol Rev 12: 19-39, 1999.
20. Garza KM, Chan SM, Suri R, Nguyen LT, Odermatt B, Schoenberger SP and Ohashi PS: Role of antigen-presenting cells in mediating tolerance and autoimmunity. J Exp Med 191: 2021, 2000.
21. Kyburz D, Aichele P, Speiser DE, Hengartner H, Zinkernagel RM and Pircher H: T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur J Immunol 23: 1956, 1993.
22. + T cells: CD4-independent help. J Immunol 167: 1283-1289, 2001.
23. + T cells in vivo. J Immunol 169: 5622-5629, 2002.
24. Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM and Wu TC: Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60: 1035-1042, 2000.
25. Hsu KF, Hung CF, Cheng WF, He L, Slater LA, Ling M and Wu TC: Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther 8: 376-383, 2001.
26. Singh-Jasuja H, Hilf N, Scherer HU, Arnold-Schild D, Rammensee HG, Toes RE and Schild H: The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells. Cell Stress Chaperones 5: 462-470, 2000.
27. Binder RJ, Han DK and Srivastava PK: CD91: a receptor for heat shock protein gp96. Nat Immunol 1: 151-155, 2000.
28. Delneste Y, Magistrelli G, Gauchat J, et al: Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 17: 353-362, 2002.
29. Huang Q, Richmond JF, Suzue K, Eisen HN and Young RA: In vivo cytotoxic T lymphocyte elicitation by mycobacterial heat shock protein 70 fusion proteins maps to a discrete domain and is CD4 (+) T-cell independent. J Exp Med 191: 403-408, 2000.
30. + memory response by heat shock fusion protein. Clin Vaccine Immunol 14: 1013-1023, 2007.
31. Barrios C, Lussow AR, Van Embden J, et al: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guérin priming. Eur J Immunol 22: 1365-1372, 1992.
32. Suzue K and Young RA: Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J Immunol 156: 873-876, 1996.
33. Calderwood SK, Theriault JR and Gong J: Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity. Eur J Immunol 35: 2518-2527, 2005.
34. Tobian AA, Harding CV and Canaday DH: Mycobacterium tuberculosis heat shock fusion protein enhances class I MHC cross-processing and - presentation by B lymphocytes. J Immunol 174: 5209-5214, 2005.
35. Li Y, Subjeck J, Yang G, Repasky E and Wang XY: Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Vaccine 24: 5360-5370, 2006.
36. Van Eden W, Koets A, van Kooten P, Prakken B and van der Zee R: Immunopotentiating heat shock proteins: negotiators between innate danger and control of autoimmunity. Vaccine 21: 897-901, 2003.
37. Rook GA, Martinelli R and Brunet LR: Innate immune responses to mycobacteria and the downregulation of atopic responses. Curr Opin Allergy Clin Immunol 3: 337-342, 2003.
38. Nichols WW, Ledwith BJ, Manam SV and Troilo PJ: Potential DNA vaccine integration into host cell genome. Ann NY Acad Sci 772: 30-39, 1995.
39. Lukas J, Müller H, Bartkova J, et al: DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J Cell Biol 125: 625-638, 1994.
40. Osen W, Peiler T, Ohlschlager P, et al: A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine 19: 4276-4286, 2001.
41. Shi W, Bu P, Liu J, Polack A, Fisher S and Qiao L: Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J Virol 73: 7877-7881, 1999.
42. Smahel M, Sima P, Ludvikova V and Vonka V: Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281: 231-238, 2001.
43. Liu WJ, Gao F, Zhao KN, Zhao W, Fernando GJ, Thomas R and Frazer IH: Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity. Virology 301: 43-52, 2002.
44. Young RA: Stress proteins and immunology. Annu Rev Immunol 8: 401-420, 1990.
45. Sinha AA, Lopez M and McDevitt HO: Autoimmune diseases: the failure of self tolerance. Science 248: 1380-1388, 1990.